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INTRODUCTION 
 
 
Coronary artery disease is prevalent worldwide, and many in India are 
also affected due to the increasing sedentary lifestyle and high prevalence of   
diabetes and hypertension...  
 
 In patients with coronary artery disease, induction of anesthesia is 
challenging because the circulatory system cannot tolerate depression. The 
main aim should be to avoid hypotension, minimize the stress response to 
laryngoscopy and to maintain the balance between myocardial oxygen supply 
and demand. This challenge is exaggerated when you are dealing with a patient 
whose left ventricular function is impaired. Avoidance of hypotension is 
crucial as it is associated with increased morbidity and mortality.  Induction of 
anesthesia is associated with loss of sympathetic tone, and myocardial 
depression. Hypotension has been defined as a decrease in mean arterial 
pressure (MAP) less than 60 mm Hg or a decrease of > 40% from the base line.  
An episode of hypotension lasting for more than 1.5 minutes is shown to be 
associated with a 13.3 % increase in hospital stay and 8.6% increase in death. 
Intraoperative hypotension has been shown to be associated with myocardial 
ischemia as evidenced by elevated troponin T levels(1).Intraoperative 
hypotension is associated with the occurrence of myocardial ischemia as 
evidenced by elevated Troponin levels. Given the high risk of poor outcomes 
due to post induction hypotension, an ideal induction agent should be the one 
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which produces minimal changes from baseline hemodynamic variables and 
suppresses the stress response to intubation. 
Normally laryngoscopy and intubation produce hypertension and tachycardia 
or rarely bradycardia as result of autonomic stimulation which can jeopardize 
the balance between myocardial supply and demand. Suppression/ minimizing 
this response is an important aspect of anesthesia induction.  
 
However our search for an ideal agent is still far from reality. 
 Various intravenous drugs are used for induction of anesthesia in these 
patients, the common ones are thiopentone, propofol, ketamine, etomidate and 
midazolam. We have to select an anesthetic that has the balance between 
prevention of hypotension and avoiding a surgical stress response. Etomidate 
has a stable cardiovascular profile and is considered by many as an ideal 
induction agent in patients with significant coronary artery disease and left 
ventricular dysfunction. Use of Etomidate is associated with adrenal 
suppression even after single dose. Cortisol which is a stress hormone, is also 
involved in maintaining the vascular tone, gets suppressed by etomidate. So, 
there can be increasing requirement of vasopressors postoperatively and may 
lead to poorer outcome in patients with sepsis. However the evidence is 
conflicting. 
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Midazolam is another induction agent with good cardiovascular stability and is 
effective in suppressing the stress response to laryngoscopy and intubation. 
However, combining midazolam with fentanyl may result in hemodynamic 
instability. 
 
We propose a study to compare etomidate and midazolam for induction 
of anesthesia in patients with impaired left ventricular function undergoing 
coronary artery bypass graft. We will compare the effects of these drugs on 
hemodynamic stability and the ability to prevent intubation response. We will 
also study whether the use of etomidate results in significant adrenal 
suppression and general outcomes. 
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AIMS AND OBJECTIVES 
 
 
¾ Primary aim:  
1. To compare the effects of Etomidate and Midazolam on hemodynamic 
stability during induction of anesthesia in patients with impaired left ventricular 
undergoing Coronary artery bypass grafting. 
 
2. To compare their efficacy in minimizing hemodynamic response to    
intubation.  
 
¾ Secondary aim:  
 To measure serum cortisol levels in both group of patients to see if there is 
any adrenal suppression with a single dose of etomidate used during induction. 
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REVIEW OF LITERATURE 
 
Global burden  
Coronary artery disease is a leading cause of death and disability in 
developed countries. Over the age of 35, one third or more of the mortality is 
due to ischemic heart disease. The prevalence of coronary artery disease 
worldwide is 70%. There are so many risk factors which promote coronary 
artery disease like smoking, dyslipidemia, diabetes, and hypertension. 
 
In 2010 the American Heart Association, Heart Disease and Stroke 
Statistics(NHANES) in an update has reported that IHD prevalence to be 17.6 
million .Among them myocardial infarction(MI) prevalence was 8.5 million 
and the prevalence of angina pectoriswas 10.2 million (2).In both sexes there 
was a progressive increase in the prevalence. Since 1990  there was a  41% 
increase of deaths due to cardiovascular disease,  that is 17.3 million deaths 
worldwide.(3) The age-standardized death rate has decreased by 22 percent in 
the same period. 
 
During 1988-1994 and 1999-2004 time periods, in age group of 35-54 
years, prevalence of MI was compared against sexin a NHANES data 
2009report. It was found that men had a greater prevalence than women in both 
the time period  (2.5 in men versus 0.7 in women, and 2.2 in men versus 1.0 in 
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women) and there was a declining trend in men and increasing trend in 
women.(3) 
INCIDENCE 
In the original Framingham study,for an individual aged more than 40 
yearsin a cohort of 44 years of follow up, the lifetime risk to develop CHD is 
49 percent in men and 32 percent in women (4–6).The risk was found to be  35 
percent in menand 24 percent in women, in individuals nearing 70 years. The 
incidence of coronary events increases with age, in women MI presents later by 
about 10 years.  Women lag behind men in incidence by 20 years in the 
incidence of MI and sudden death. 
 
The incidence at ages 65-94years compared to ages 35-64 years, more 
than doubles in men and triples in women (7–9).The annual incidence rate  was 
found to be 12 per 1000 in men below 65 years of age, this  was more than the 
rate of all the other atherosclerotic cardiovascular events combined (7 per 
1000); in women, it equals the rate of the other events (5 per 1000). After 65 
years of age, the leading health problem among the elderly is coronary artery 
disease. Of the atherosclerotic cardiovascular events in men, coronary events 
form 33 to 65 percent and 28 to 58 percent in women. Below 75 years of age in 
women, coronary disease presents  more often as angina pectoris than MI. 
(5,6).Having said that, 80% angina in women is more often uncomplicated 
whereas 66% of angina in men often occurs after a MI.At all ages in men, 
myocardial infarction occurs, among them 20 % have pre-existing long-
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standing angina. If the MI is silent or unrecognized, the percentage  is even 
lower (5,6).  
An analysis from the (NHANES) I Epidemiologic Follow-up study 
compared two cohorts of subjects, from 1971 to 1982 (10,869 patients) and 
from 1982 to 1992 (9774 patients)(10) . In the yearly follow up per 10,000 
persons, the incidence of CHD decreased from 133 to 114 cases. There was an 
overall large decline in cardiovascular disease (from 294 to 225 cases per 
10,000 persons per year). In Olmsted County, Minnesota,a report from the 
Mayo Clinic examined the incidence of CHD over time (11). During the 
interval from 1988 to 1998, there was a decrease from 57 to 50 cases per 
10,000 persons in the age-adjusted incidence of any new coronary diseaselike 
MI, sudden death, unstable angina, or angiographically diagnosed CHD 
(relative risk 0.91, 95% CI 0.82-1.01). 
In 2014 in a  study done by World Health Organization, it was found 
that over 4 million annual deaths are due to cardiovascular disease, from data  
collected from 49 countries in Europe and northern Asia(10). 
• In India, the prevalence of ischemic heart disease could not be fully 
explained by traditional risk factors (12). 
• In China, due to higher cholesterol levels, there have been an increase in 
CHD mortality in Beijing.  
•  Due to a higher prevalence of physical inactivity, obesity and smoking in 
Latin America,the vascular disease rates are comparatively higher than the 
United States.(13). 
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There has been a relative increase in non-ST elevation MI (NSTEMI) in 
relation to ST elevation MI with time  (14–16) . For example, a report from the 
National Registry of Myocardial Infarction 1 to 5 reviewed over 2.5 million 
MIs between 1990 and 2006(14) and found that the proportion of MIs due to 
NSTEMI increased from 19 percent in 1994 to 59 percent in 2006. This change 
in proportion was associated with an absolute decrease in the incidence of 
STEMI and either a rise (using MI defined either CK-MB or troponin criteria) 
or no change (using MI defined using only CM-MB criteria) in the rate of 
NSTEMI.(13) 
 
INDIAN BURDEN OF DISEASE 
 India is going through a phase where the communicable disease is 
decreasing, and the non -communicable diseases are on the rise. This has led to 
a dual burden. There has been a disturbing increase over the few years in the 
prevalence of cardiovascular disease in India and South-east Asia. In India, the 
prevalence over the past 40 years has increased 4-fold. In a study done from 
across the country ,the prevalence was found to be 7-13% in urban(17,18) and 
2-7% in rural(19,20) regions .In Chennai the deaths due to cardiovascular 
causes was highest at 38.6% .Cardiovascular deaths were highest in Chennai 
38.6% as reported by Gajalakshmi et al (21) . 
The Global Burden of Diseases Study has reported thatduring 1990 the 
disability-adjusted life years lost due to CHD in India was 5.6 million in men 
and 4.5 million in women; it is expected to rise to  14.4 million in men and 7.7 
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million in women respectivelyby 2020.(22) Risk factors of CAD like 
dyslipidemia, central obesity, hypertension,diabetes, physical inactivity and 
smoking has beenalarmingly increasingwhich explains the overpowering 
disease burden. Over the past two decades, there has been rapid urbanization 
and lifestyle change.Previous studies which were done in migrant Indians were 
misinterpreted that they are genetically preordained to develop the disease and 
that conventional risk factors do not contribute to the CHD prevalence among 
Indians(23).The high prevalence and occurrence of CHD prematurely cannot 
be attributed to the conventional risk factors. 
 
However, the large INTERHEART study an international study 
recruiting 30,000 people from 52 countries, found that  most of the CHD 
burden was due to  conventional risk factors.(24) It also recruited a large 
number of Indians. The aim was to establish the risk factors associated with 
myocardial infarction .The influence of factors like nationality, sex and age on 
the prevalence was studied. The secondary aim was to find the overall 
population attributable risk and in various subgroups. The influence of obesity, 
physical inactivity, alcohol consumption was studied. It was seen that at the age 
of 40 or younger, the first attack of MI was seen in the Middle East and Africa 
and South Asia with an incidence of 12.6, 10.9, and 9.7 
respectively.Psychosocial factors, abdominal obesity, diabetes, hypertension, 
dietary patterns and waist-hip ratio were the next most important risk factors in 
men and women.  
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There are over 32 million diabetics in India. In 2025it may reach 57.2 
million.(25)In 2000 it was reported that the prevalence of type2 diabetes in 
urban Indian adults has increased from less than 3.0% in 1970 to about 12.0% 
in 2000(26).In a survey done by ICMR the prevalence of diabetes was 3.8% in 
rural areas and 11.8% in urban areas. In 2025, the count of  hypertensives will 
rise from 118 million in 2000 to 214 million.(27) 
 
 Globalization due to increasing connectivity among countries, 
increased trade and finances, acceptance to ideashave contributed to the disease 
burden. In the last decade, the prevalence and production of tobacco products 
has increased by more than double in the developing world compared to 36% 
reduction in the developed world.  
Among the 1.1 billion smokers worldwide, India accommodates 182 million. In 
tobacco production and consumption, India is the third largest country in the 
world, in both tobacco production and consumption.(28) The production of 
tobacco products have increased markedly in the developing countries.Except 
the poorest countries, all other countries have replaced the traditional diet rich 
in fruit and vegetables by a diet rich in calories provided by animal fats and 
low in complex carbohydrates. Such changes will in general lead to increased 
rates of many non-communicable diseases, although not necessarily stroke 
rates. 
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HISTORY OF CARDIAC SURGERY 
 In 1801,Francisco Romero ,in 1810 Dominique Jean Larrey,in 
1891,Henry Dalton and in 1893,Daniel Hale Williams were the first ones to 
operate on the pericardium. On 4 September 1895, in Rikshospitalet Kristiania, 
the first surgery on the heart was performed by a Norwegian surgeon Axel 
Cappelen . On September 7, 1896, Dr. Ludwig Rehn of Frankfurt, Germany, by 
repairing a stab wound to the right ventricle did the first successful surgery on 
the heart. After World War II, cardiac surgery changed significantly .In 1948, 
four surgeons independently did work on mitral valve repair. In 1947, Thomas 
Holmes Sellors operated on a Fallot's tetralogy in Middlesex hospital. Dr. 
Wilfred G. Bigelow found out that a motionless and bloodless field made the 
repair of intracardiac pathologies easier. Correction of congenital heart disease 
was done by Dr. C. Walton Lillehei and Dr. F. John Lewis at the University of 
Minnesota on September 2, 1952.In 1956 Dr. John Carter Callaghan performed 
a number of firsts in heart surgery, including the first documented open-heart 
surgery in Canada. The first successful use of extracorporeal circulation by 
means of an oxygenator was reported by Dr. John Heysham Gibbon at 
Jefferson Medical School in Philadelphia in 1953. 
 
Coronary Artery disease 
Coronary artery disease is most commonly defined as more than 50% 
luminal stenosis of any epicardial coronary artery. It is most commonly due to 
atheromatous plaque. Coronary artery disease manifests as stable angina, acute 
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coronary syndrome, congestive heart failure, silent ischemia and sudden 
cardiac death. 
 
Acute coronary syndrome ranges from unstable angina to STEMI. It 
results from acute thrombosis of coronary artery at the site of atheromatous 
plaque rupture or ulceration. 
 
SYNTAX is the most important trial of CABG and PCI .Report of the 
final 5 year follow up by Friedrich Mohr et al is as follows:  
 
There was a significant difference in Major adverse cardiac and 
cerebrovascular events (MACCE) .It was 26·9% in the CABG group versus 
37·3% in the PCI group (p<0·0001). 
 
The incidence of cardiac death was 5·3% vs9·0% with p=0·003, 
myocardial infarction was 3·8% vs9·7% with p<0·0001, and repeat 
revascularisation 13·7% vs. 25·9% with p<0·0001.There was  no significant 
difference in all-cause death (11·4%vs13·9%; p=0·10) or stroke (3·7% vs2·4%: 
p=0·09)(29) 
 
CABG SURGERY  
In 1910 A. Carrel attempted the first CABG in animals. In1954, 
G. Murray used the internal mammary artery (IMA) as a graft in CABG. R. 
Goetz performed the first reported CABG using the IMA in humans .He used 
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the suture less technique in 1960. The technique of sutured bypass grafting was 
introduced in 1964 by V. Kolessov. From 1962 to 1967, saphenous vein was 
used as autogenous graftsin CABG.  By 1990s Off-pump coronary artery 
bypass came into existence. This was done without cardiopulmonary bypass. 
The goal is to revascularize the area of myocardium that was perfused 
previously by coronary arteries with a stenosis of more than 50%.A durable 
conduit is needed for this purpose. 
A systemic inflammatory response is triggered in patients undergoing 
cardiothoracic surgery with cardiopulmonary bypass (CPB) as a result of the 
combination of surgical trauma, activation of blood components in the 
extracorporeal circuit, ischemia/reperfusion injury, and endotoxin release(30–
33)There is evidence for activation of all the body’s major host defensive 
pathways, including complement, coagulation, kinins, fibrinolysis, leukocytes, 
platelets, and inflammatory cytokines (33–42). This broad wave of systemic 
activation has been linked to adverse clinical outcomes ranging from mild 
adverse effects (fever or diffuse tissue edema), to moderate adverse effects 
(pathological hemodynamic instability or coagulopathy), to severe 
complications (acute organ injury requiring mechanical support), and even 
mortality (43–45).The sympathetic nervous system stimulates the 
cardiovascular system. This causes catecholamine levels to increase leading to  
tachycardia and hypertension, which can cause  myocardial ischemia and 
infarction(46–48).Short lived effects can have dire consequences on the 
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coronary circulation of high-risk patients causing morbidity and 
mortality.(49,50). 
 
A best available summary of the evidence suggests that the use of 
OPCAB may reduce myocardial injury (troponin and CKMB), but this could 
not be linked in an obligate relationship with inflammatory suppression.(51) 
There were eight RCTs on approaches to minimize the surface area of the 
extracorporeal circuit, and three of these eight achieved clinical benefit. There 
were 14 RCTs examining different biocompatible surface coatings of which six 
indicated a clinical benefit. Heparin was the most widely studied biocompatible 
coating plus one paper was a direct comparison of two different types of 
heparin-coated circuits. Poly-2-methoxyethylacrylate and amphophilic 
silicone–caprolactone oligomer were also studied as surface coatings. There 
were eight RCTs studying leukocyte depletion, seven of which used the same 
arterial line leuko-depleting filter. Two of these eight studies were assigned a 
clinical benefit. There were 13 RCTs and one Cochrane database review (52)on 
steroid interventions. Among the 13 RCTs, three were assigned a clinical 
benefit. Five RCTs investigated the use of complement inhibitors, three of 
which found a clinical benefit. There was one RCT and one meta-analysis for 
aspirin given preoperatively, and neither study was able to demonstrate a 
clinical benefit.  
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There were three RCTs examining different methods to deliver nitric 
oxide (NO) to patients perioperatively: all demonstrated clinical benefit. There 
were three RCTs examining administration of neutrophil elastase inhibitors 
were adjudged clinically beneficial. There were two RCTs studying propofol 
anesthesia. Both studies demonstrated a clinical outcome improvement. There 
were two RCTs from the same research group on the bronchodilator 
aminophylline. Both of these small studies (n = 30) demonstrated a clinical 
benefit. There were two RCTs on sevoflurane anesthesia, only one of which 
demonstrated an improvement in a clinical outcome. There was one RCT on 
intensive insulin therapy using the Portland Protocol(53) in patients with no 
history of diabetes. This well-designed study (n = 100) showed a clinical 
benefit with significantly shortened intensive care unit stay and myocardial 
protection. There was one RCT on fluvastatin administered for 3 weeks up to 
the day of surgery; this study demonstrated clinical benefit. There was one 
RCT on propionyl L-carnitine administration in a diabetic cohort, 
whichassigned a clinical benefit for this intervention. There were three RCTs 
on ultrafiltration using three different ultrafiltration techniques. However, none 
of the trials recorded a significant depletion of inflammatory biomarkers and 
none achieved a clinical benefit. There were no indications of negative patient 
outcomes. 
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Induction of anesthesia 
Propofol, Etomidate, barbiturate, acts on γ-aminobutyric acid type A 
receptors. A state of sedation is induced with a small dose of propofol, 
barbiturate, and etomidate (54).When the drug is given, it causes 
excitation.(55).At that time there are random movements, mumbled speech, 
and euphoria. It is accompanied by an increase in beta activity on EEG.(13 to 
25 Hz)(55–58).This state is called paradoxical because the drug causes 
excitation instead of unconsciousness. 
 
As the induction agent is given over 10-15 seconds, respiration becomes jerky, 
bag and mask ventilation is started to support breathing. Simultaneously,the 
patient becomes unresponsive,and muscle tone is lost. Further on, when the 
anesthesiologist asks the patient to follow the finger, eye movements stop, and 
nystagmus may occur and there is increased blinking. Oculocephalic and 
eyelash reflex, corneal reflex is also lost(83) However, pupillary reflex remains 
intact.(84). There can be fluctuations in blood pressure, while tachycardia 
occurs. Opioid or benzodiazepines are given to suppress the tachycardia, 
vasopressors are given to maintain blood pressure. 
 
Problems during induction 
There is no standard definition of intraoperative hypotension, as a result 
it is difficult to assess the incidence across various studies. Hypotension mostly 
occurs between start of induction and starting of surgery. Various parameters 
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have been analyzed   such as baseline variation, a decrease in systolic arterial 
pressure or mean arterial pressure (MAP) under a set-point, combination of 
parameters, period of hypotension, and vasopressor requirement or fluid 
requirement.(61)It was found that hypotension occurs in 5-99% of patients 
during anesthesia (Bijker et al) (61).There have been no clear definitions of the 
threshold and duration of hypotensive episodes which can lead to 
complications. 20% or more Systolic arterial pressure decrease is defined as 
perioperative hypotension .In their study, Reich et al showed that hypotension 
occurred more often 5–10 minutesafter induction rather than the initial  0–5 
minute period(62).A decrease in MAP more than 40% or <70 mmHg, or <60 
mmHg is defined as hypotension.The incidence of hypotension was 7.7% in 
ASA I–II, 12.6% in ASA III–V patients respectively. Various predictors of 
hypotension included: ASA III-V, MAP <70 mmHg, age ≥50 years, high dose 
fentanyl and propofol use at induction .Many studies have indicated that 
cardiac complications result from hemodynamic instability during surgery. 
Acute intraoperative hypertension alone is not known to cause complications. 
A MAP decrease  of 40% or <50 mmHg MAP intraoperatively are associated 
with coronary events in high-risk patients.(63). After a noncardiac surgery 
,episodes of MAP <55mm Hg which are short lived can cause acute kidney 
injury and myocardial ischemia.(64)The blood pressure threshold and duration 
which can be associated witha perioperative stroke is not established 
yet.(65)Hypotension at the time of surgery,is the most frequent  causative 
factor related to mortality in anesthesia.(66) 
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Stress response to intubation 
Laryngoscopy and endotracheal intubation forma major part of general 
anesthesia for cardiac surgery (67). Laryngoscopy and orotracheal intubation 
are potent stimuli, which can provoke hemodynamic response like hypertension 
and tachycardia which can lead to myocardial ischemia, ventricular arrhythmia, 
left ventricular failure and cerebral hemorrhage. The mechanism of these 
responses is explained by somatovisceral reflexes. During laryngoscopy, 
stimulation of proprioceptors at the base of the tongue, induces impulse 
dependent increase in blood pressure, heart rate, and catecholamine surges. 
Repeated orotracheal intubation elicits augmented hemodynamic and 
epinephrine responses and some vagal inhibition of the heart. These incidences 
are harmful in such a group of patients like coronary artery disease, cardiac 
arrhythmias, cardiomyopathy, congestive heart failure, hypertension and 
geriatric population. To suppress the stress response to laryngoscopy and 
intubation various drugs like barbiturates, calcium channel blockers, 
vasodilators, beta blockers, and opioids have been tried at regular intervals. 
Hence there is a need to attenuate hemodynamic responses to laryngoscopy and 
surgery without undue hypotension. 
 
In 1940, Reid and Brace,first described a hemodynamic response to 
laryngoscopy and intubation(68).It leads to an average increase in blood 
pressure by 40-50% and 20% increase in heart rate (69).The increase in blood 
pressure and heart rate is usually transient and variable, but can be 
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unpredictable and life-threatening if left unaddressed. For most patients, the 
hemodynamic response to the stress of laryngoscopy and endotracheal 
intubation does not present a problem(70).However, cardiac patients respond to 
anesthetic induction and endotracheal intubation with an increase of blood 
pressure and heart rate and are more prone to develop hemodynamic instability 
(71). The delicate balance between myocardial oxygen demand and supply is 
altered due to hemodynamic changes caused due to intubation .This may 
precipitate myocardial ischemia in patients with coronary artery disease (129). 
Laryngoscopy itself is one of the most invasive stimuli during endotracheal 
intubation (70,72). Many anesthesiologists agree that a skilled anesthesiologist 
applies only a small force to the patient’s larynx when using a laryngoscope 
and that reducing the force on the larynx might prevent excessive 
hyperdynamic responses to endotracheal intubation (73–75).After seconds of 
direct laryngoscopy, hemodynamic changes occur, leading to further increase 
in heart rate and blood pressure with passage of the tracheal tube.The first is 
the response to laryngoscopy and the second is the response to endotracheal 
intubation. The component which is responsible for the hyperdynamic response 
is not known. Singh et al., while doing a study on different induction agents in 
Coronary artery disease, showed that stress response on intubation was most 
obviouswhen etomidate was the induction agentin patients with coronary artery 
disease while midazolam was most effective in preventing intubation 
stress(76).  Hemodynamic changes were lesser when intubation was done with 
the Airtraq, when compared to the Macintosh laryngoscope (77,78). Thus, 
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many studies have focussed on stress response to endotracheal intubation, high 
doses of opioids, α2-adrenergic receptor agonists, β-adrenergic blocking drugs 
or other antihypertensive drugs and a number of drugs have been used to 
suppress the hemodynamic response(48,49,79–89) 
 
A wide variety of pharmacological agents were used to attenuate the 
hemodynamic responses to laryngoscopy and endotracheal intubation like 
lignocaine,(90),fentanyl(91),alfentanil,(92),remifentanil,(143)nifedipine,(93) 
beta-blockers,(94) gabapentin,(95)magnesium sulfate,(96) verapamil, 
nicardipine, diltiazem(97)with varying results. Previous studies(97–101)have 
also documented that nitroglycerin does not attenuate the rise in heart rate after 
intubation, which can be attributed to reflex tachycardia produced by 
vasodilation. The principal advantage of using nitroglycerin is that, while a 
desirable and transient hypotension is achieved, cardiac output is not likely to 
decrease. Preload reduction and accompanying decrease in ventricular end-
diastolic pressure(98), reduces myocardial oxygen demand and increases 
endocardial perfusion by dilating the coronary vessels. NTG may increase the 
coronary blood flow and oxygen delivery to the myocardium. Because of its 
predominantly venodilatory action, it seems to be the best choice in patients 
with low cardiac output and moderately elevated resistance.(102) 
 
Myocardial oxygen consumption or demand (as measured by the 
pressure-rate product, tension-time index, and stroke-work index) is decreased 
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by both the arterial and venous effects of nitroglycerin resulting in a more 
favorable supply-demand ratio(98).Esmolol given IV in a dose of 1 mg kg-1 
before intubation suppressed the stressor response due to intubation (Bostana 
and Eroglu (2012)(103). Lidocaine has been a popular agent for attenuating 
circulatory responses. Lidocaine causes depression of cardiovascular system 
and vasodilation of the peripheral vasculature (104).The airway reflexes due to 
tracheal irritationare attenuated .Its analgesic and antiarrhythmic action have 
been fully made use of in cardiac anesthesia.The effects have been shown to be 
beneficial in some(105) while other studies indicated that there is no effect 
when it is given 1-3 minutes before the time of laryngoscopy 
(106,107).Lidocaine in a dose of 1.5 mg/kg and esmolol in a dose of 2 mg/kg 
were effective in attenuating the response to laryngoscopy and intubation. 
There were no harmful effects reported.Tachycardia and hypertension are 
known to contribute to myocardial infarction perioperatively and is an 
important factor leading to morbidity and mortality(108).Hence it can be 
concluded that the quest for ideal induction agent is still elusive. 
 
 
Hemodynamic goals in CABG 
After induction and intubation, there is hypotension and there is intense 
surgical stimulus like skin incision and sternotomy that produces hypertension, 
tachycardia. Themain aim during anesthesia is suppression of sympathetic 
responses to laryngoscopy, intubation. Steps of surgery like skin incision, 
splitting of sternum, and spreading which can cause massive response should 
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be avoided. Anesthetic drugs cause vasodilation and depression of 
cardiovascular system, leading to hypotension which has to be prevented.One 
induction agent is not favorable for every CABG patient, and anesthesia has to 
be tailored for each individual to achieve stability in hemodynamics.(109,110) 
 
Since many years, there have been several anesthetic techniques used 
with their own adverse cardiac effects, inhalational agents at increased doses 
causing depression of cardiac system, absence of myocardial depression with 
increased doses of opioids, isoflurane causing coronary vasodilatation leading 
to steal phenomenon. Another concern is interactions due to pre-op 
medications, beta blockers causing cardiovascular depression, hypotension due 
to ACE inhibitors or ARB(111–113). The underlying principle is that oxygen 
supply and demand ratio should not be altered to avoid injury to myocardium. 
Now- a days surgical management is moving on to accelerated recovery 
protocols or fast track management (114,115). Efforts are on to improve the 
final outcome and to decrease costs which lead  to decreased duration  of in- 
hospital stay(114,115). 
 
 
High-dose opioids with benzodiazepines have been used since the 1970s 
and 1980s.Eventually volatile anesthetics became more popular, due to their 
protective effect on the myocardium. However, inhalational agents are not 
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better when compared to intravenous agents in terms of advantage in the rate of 
mortality.Hence, opioids have been given a secondary role (116,117). 
 
Patients can be optimized by 1)preoperative assessment done 
carefully,risk factor modification2) all medications should be handled properly 
in the preoperative period (3) monitoring cardiovascular system carefully, 
inserting a central venous line4) amnesia, analgesia, and muscle relaxation is 
induced 5) a smooth progress to the immediate postoperative period. The goal 
is to extubate early, mobilize the patient, and discharge early. 
During CPB, changes in hemodynamics or hormonal changes which can 
cause ischemia of the myocardium or have a harmful effect on metabolism of 
the myocardium should be prevented. Appropriate management and careful 
monitoring is required. Close interaction between the surgeon, anesthesiologist, 
is needed particularly when the heart, great vessels are being manipulated. 
 
Anesthetic goals in patients with LV dysfunction 
In patients with LV dysfunction, in order to increase blood pressure and 
cardiac output, various mechanisms are activated. To increase the circulating 
blood volume several neurohumoral pathways are activated. The sympathetics 
cause an increasein heart rate and myocardial contractility, vasoconstriction of 
the arteriolar system in splanchnic vascular system, and stimulation of the 
juxtaglomerular apparatus of the kidney to secrete renin. Activation of the 
Renin–angiotensin systemcausesvasoconstriction of the arteriolar system, 
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retention of water and sodium, and release of aldosterone. Aldosterone increase 
leads to sodium and water retention. Additionally, vasopressin released from 
the hypothalamus due to baroreceptor and osmotic stimuli, cause water 
reabsorption from the renal collecting duct. Eventually these mechanisms, even 
though they are beneficial, aggravate ischemia, dysrhythmia, cause endothelial 
dysfunction, promote cardiac remodeling and are toxic to myocytes.  
 
Any deterioration in the structure or function in the filling of left 
ventricle, or systolic ejection results in heart failure .Changes in hemodynamics 
and drugs used in anesthesia can have a harmful effect on the diastolic function 
of the left ventricle. 
Arrhythmia and myocardial ischemia affect diastolic time. Any 
preexisting dysfunction in diastole is decompensated. Diastolic time is 
shortened by tachycardia and left ventricular filling is impaired. Hypo- or 
hyper-kalaemia, anaemia, or hypovolemia cause rhythm disturbances. 
Tachycardia can be prevented by beta-blockers or calcium-channel blockers 
andleft ventricular filling is improved(118,119). 
 
Myocardial relaxation is slowed significantly when there is myocardial 
ischemia or sudden volume loading or positionchanges. Myocardial ischemia 
may cause rhythm changes which can precipitate diastolic dysfunction of the 
left ventricle. Myocardial ischemia is the imbalance between myocardial blood 
supply and demand. It can be multifactorial in cardiac surgery. It can happen 
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due to native coronary artery disease, hypotension at the time of induction, 
inadequate myocardial protection, inadequate surgical correction (poor target 
vessels, poor conduits) graft kinking and graft thrombosis. 
 
Thus, when dealing withsuspected diastolic heart failure, prevention of 
ischemic episodes should be the main stay of management. Beta-blockers are 
the best drugs known,to decrease oxygen consumption of the myocardium. The 
mortality due to coronary events overall has been decreased by use of beta-
blockers perioperatively.(120,121). It is not known whether this line of 
management is still suitable for diastolic heart failure. There have been less 
studies on the effect of intravenous agents on diastolic properties, however, the 
effect of volatile agents has been extensively studied.Left ventricular diastolic 
function is not affected by inhalational agents like sevoflurane and desflurane, 
as well as opioids or muscle relaxants.  
 
LV DYSFUNCTION AND ANESTHESIA 
Persons with a healthy heart have good cardiac function .However, 
patients with LV dysfunction have limited cardiac reserve. Since most of the 
anesthetics that we use routinely are associated with cardiovascular depression 
the anesthesiologist is placed in a very challenging situation. 
 
Anesthetics depress the sympathetics and these patients rely on the 
sympathetic system to maintain a good cardiac output. The anesthetics can 
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cause myocardial depression directly or can indirectly affect the cardiovascular 
control mechanisms. Initially it was thought that LV diastolic dysfunction was 
primarily due to systolic dysfunction, but now it is being seen that diastolic 
dysfunction alone can affect the overall performance of the heart. 
 
In a healthy heart, cardiac output is affected by changes in preload, 
however in patients with LV dysfunction, it is very sensitive to changes in 
afterload. Hence arterial vasodilation can improve cardiac output. After 
anesthetic induction, venodilation occurs leading to decreased cardiac output. 
In the absence of a coronary intervention, data suggests that before a non-
cardiac surgery,≥60 days should elapse after a MI.  MI which has occurred in 
the last 6 months before a non cardiac surgery is defined as recent MI. It was 
alsoan independent risk factor for stroke perioperatively, this was linked with 
8-times increase in the mortality rate perioperatively(122).Given the fact that 
adults more often are affected with diseases like coronary artery disease, 
stroke,and diabetes mellitus, age plays a major role(123). When they come for 
noncardiac surgery, risk of MACE increases overall. Another important risk 
factor for stroke in perioperative period is age more than 62 years (125).There 
was a higher incidence of acute ischemic stroke ,among older adult patients 
(those >65 years of age) than those ≤65 years of age  undergoing noncardiac 
surgery (124). Complications in the postoperative period was higher in those 
who had poor cognition, and who had to rely on others for activities of daily 
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living. Hence, the duration of hospital stay increased(126).A history of stroke is 
a risk factor to develop MACE perioperatively.(122) 
 
DRUGS USED FOR ANESTHESIA INDUCTION 
FENTANYL 
It was invented by Paul Janssen (1926–2003) (127–130)It is a 
derivativeof phenylpyperidine. It is 100 times more potent than morphine. It is 
an agonist at the mu receptor. It has great analgesic properties, and till it causes 
unconsciousness, producesincrease in analgesia depending on the dose given.  
Along with fentanyl,other agonists are hydromorphone morphine, and 
oxymorphone. Compared with nalbuphine, an agonist at the kappa receptor, it 
has greater effects on analgesia. (Morgan et al., 1999). The ED50 was 0.08 and 
95% limits were 0.045to 0.142 mg/kg(131).The LD50 in humans is unknown 
.After injecting, fentanyl quickly enters into theCSF.The Tmaxwas 2.5-10 
minutes.(Hug & Murphy, 1979) and the Tmax in brain was 10-20 min (Ainslie 
et al., 1979). The concentrations of fentanyl were found to be equal to that of 
plasma, later it was lower than the concentration in plasma. (Hug & Murphy, 
1979). Concentrations in brain decreased slowly than that of plasma. In a study 
by Ainslie et al in 1979, it was found that in a duration of 30 min-2 hrs during 
the study, the concentrations in brain exceeded plasma concentrations. Due to 
its lipophilic properties, great amounts of the drug are found in the 
brain.Metabolism  and excretion of H-fentanyl occurred in urine and feces,  
following IV and subcutaneous injection (132) (Ohtsuka et al., 2001).After a 
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single injection of H-fentanyl,4% of the drug and 36% of the overall  dose was 
found  in 6 hour urine collection (132)(Murphy et al., 1979).Cytochrome P450 
is responsible for metabolism. It is dealkylated to nor fentanyl (Feierman, 
1996; Feierman & Lasker, 1996; Labroo et al., 1997). Other metabolites were 
despropionylfentanyl and hydroxyfentanyl. 
 
The duration of analgesia lasts for 30 minutes. There was minimal 
depression of cerebral cortex.The alterations in respiration are long lasting than 
the effect of analgesia.At doses in therapeutic range, there was no significant 
cardiovascular effects. Fentanyl binds to human plasma proteins and rapidly 
distributes with sequestration in fat. Metabolism occurs in the liver and 
excretion through the kidney. Elimination half-life ranges from 6 - 32 h. After 
intravenous injection the effect starts quickly, and it takes 7 to 8 mins after 
intramuscular dose. After IV injection, it peaks in 5 to 15 min. Duration of the 
analgesic effect lasts for 1 to 2 hrs on intramuscular administration.In contrast 
to morphine,the onset is fast and duration of action is short. 
 
With other opioids and CNS depressants it acts synergistically. 
Tolerance develops with repeated use. This leads to increase in the minimal 
effective dose. Over a few days, physical dependence develops. Side effects are 
nausea, vomiting, bradycardia, depression of respiration and chest wall rigidity 
(133–135). 
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They act synergistically with anesthetics and reduce dose requirement of 
anesthetic agents. It does not cause myocardial depression, so it is invaluable in 
LV dysfunction. It has definite cardio protective actions like antiarrhythmic 
activity especially in ischemic reperfusion injury. Due to its action on δ- and κ-
opioid receptors there is prolongation of the cardiac action potential 
duration.(136)Remifentanil and fentanyl both induce preconditioning of the 
myocardium, even though their action at δ- and κ-opioid receptors are weak.  
Reducing the dose of anesthetic drugs is often the safest way to induce patients 
with LV dysfunction. Large doses of fentanyl as the only anesthetic have the 
advantage of stable hemodynamics ,there is lack of direct depression on the 
myocardium, withno release of histamine and stress response to surgery is 
suppressed(137).There are  no changes in the contractility of myocardium. 
After large doses of fentanyl, hemodynamic variables remained unchanged. 
Fentanyl may depress cardiac conduction by direct membrane 
actions.(138).During induction in patients undergoing CABG, QT interval was 
found to be prolonged. Conductance in coronary circulation is regulated by 
arterial baroreceptors. This is increased  by low fentanyl concentration in 
plasma, but it is suppressed with high  fentanyl plasma 
concentrations(139).Studies in dogs showed a direct peripheral vessel smooth 
muscle relaxation(140) .Its antiarrhythmic potential, anti-ischemic action  and 
action on opioid receptors  was demonstrated in rabbits, (141) 
 
36 
 
In mitral valve surgery, Fentanyl was used as the only anesthetic in 
doses of 50-100 pg/kg. (STANLEX & WEBSTER 1978) and CABG (LUKN et 
al. 1979). Thehemodynamic stability was good as there is lack of myocardial 
depressant effect. Fentanyl in dose of 50-70 pg/kg caused deep surgical 
anesthesia, as seen in EEG, no awareness was being reported. (SEBEL et al. 
1981) 
 
To achieve stability in hemodynamics, opioids in high dose and 
anesthetic agents in a low dose were used to suppress the response to surgery 
(Ruggeri et al., 2011).It did not cause  depression of the myocardium (Howie et 
al., 2001; Rauf et al., 2005 and Steinlechner et al., 2007). However, opioids in 
increasing doses do not suppress the surgical stress response, the plane of 
anesthesia has to be modified (Howie et al., 2001). 
 
In the myocardium, metabolism of phosphates was blocked in a study by 
VAN DEK VUSSE et al. (I 979) whenischemia was caused in dogs, and 
showed that it could be explained by the negative chronotropic effect of 
fentanyl.When high doses of fentanyl are used, metabolic and hormonal 
changes were decreased.During gynaecological surgery, there was a decrease 
in metabolic and hormonal changes as demonstrated by HALL et al. (1978).In 
the stage before bypass, it diminishes the endocrine and hyperglycemic 
response to surgical stimuli. During bypass, there was significant increase in 
catecholamines (SEBEL et al. 1981b). Similar study was done by STANLEY 
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et al. (1980).Stress response was higher when fentanyl was given in a low dose, 
with associated coagulopathy, and required more transfusion. Fentanyl at high 
doses were favorable in preventing stress response.There was better analgesia 
post operatively, when dexmedetomidine was added to fentanyl at low doses 
vs. low dose fentanyl, in preventing response to stress(142).It may cause 
prolongation of recovery due to respiratory depression, as it gets accumulated. 
(Lison et al., 2007).In cardiac patients with high risk, Remifentanil has been 
used successfully (Lehmann et al., 1999). Recovery was rapid when 
remifentanil infusion was given for a long time (Ruggeri et al., 2011). 
 
Midazolam at a dose of 0.075 mg/kg or 0.15 mg/kg IValong with high-
dose fentanyl caused decrease in the mean arterial pressure by 24-32% from the 
baseline rapidly. Minor to moderate decreases in mean arterial pressure was 
observed when midazolam was used as the sole induction agent (143–
145)along  with low doses of fentanyl (144)in cardiac patients;  peripheral 
vascular resistance decreases caused by the midazolam causing drop in BP 
(144).When high doses of midazolam more than 1 mg/kg are given, it 
hasnegative inotropic effects on the myocardium (146).Since the combination 
of midazolam and fentanyl caused significant hypotension, a loading dose of 3-
5 mcg/kg was given during induction in our study, as hypotension is 
detrimental to patients with left ventricular dysfunction. When fentanyl is used 
as the sole anesthetic, the disadvantages are failure to prevent sympathetic 
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stress response, unpredictable amnestic effects leading to recall, and 
postoperative ventilatory depression.(147–149). 
 
Fentanyl is available as transmucosal and transdermal forms. Intrathecal 
fentanyl in labor can produce good analgesia. Side effects include bradycardia, 
seizure-like activity, in head injury patients is associated with increase in 
ICP.(137) 
 
PROPOFOL 
It was developed at Imperial Industries in UKwhen the effect of phenol 
derivatives to cause sedation in animal models was discovered. In January 
1973,its  properties as an anesthetic agent were discovered(150,151). The 
chemical name is   2, 6- diisopropylphenol and the weight of a molecule is 
178.27.At a pH of 6-8.5, the octanol and water partition coefficient is 6761 .At 
a pKa of 11,the formulation is in anoil-in-water emulsion, which is white, as it 
is  not soluble in water. All fat soluble anesthetic agents can be delivered, 
bacteria proliferate easily in that media.After contamination, there is risk of 
sepsis .It acts on GABA receptors(152).This was first observed  by Collins et. 
al. in 1988 (153).The strong point of propofol is its fast onset and  fast offset 
due to it’s short, context-sensitive half time. The onset of action is dose 
dependent 9-51 seconds, the peak effect is seen at 90-100 seconds. The initial 
t1/2 is 1-8 minutes, terminal t ½ is 4-7 hrs. Adose of 2 - 2.5 mg/kg  
causessystolic BP to drop by 25% -40% (154).  Mean and diastolic blood 
pressure also falls which is due to vasodilation of the arterial system. There is 
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reduced vascular tone.It may also affect myocardial contractility and autonomic 
control of cardiac output (155).There is decrease in systemic vascular 
resistance in arteries and veins, so  preload and afterload are reduced.The 
pulmonary arterial and capillary wedge pressure  decrease in cases of valvular 
heart disease (156).The effect is more in hypovolemic patients and in the 
elderly. 
It causes decrease in systemic blood pressure, decrease in sympathetic 
tone of vasculature, and decrease in SVR, with no effect on myocardial 
contractility.(157,158).This explains the cardiovascular depression, revealed as 
a reduction in arterial blood pressure .Calcium is taken up into thesarcoplasm 
which explains the negative inotropy. At usual doses, the effect on myocardium 
is not significant.Propofol   concentrations in blood decreased slower than 
thiopentone as the tissue and blood distribution coefficient was higher(5.94). 
 
There is   negative inotropic effect depending on dose.It causes decrease 
in preload of LV,afterload and stiffness of regional chambers, causes LV filling 
to be impaired. 
 
It protects the myocardium against injury by ischemia and reperfusion. 
It inhibits KATP channels at 5-15 times high concentrations at that of clinically 
used concentrations. 
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It has a free-radical scavenging property similar to vitamin E as the 
structure is similar. Free oxygen radicals are scavenged,decreases disulfide 
bonds in proteins. In organelles it prevents lipid peroxidation caused  by 
oxidative stress.(159–161)Due to its antioxidant and free radical scavenging 
nature, it protects the myocardium, which was demonstrated in experiments. 
Propofol causes significant cerebral vasoconstriction according to the dose 
given. It causes  cerebral blood flow to decrease, oxygen demand is decreased 
and any pre-existing cerebral edema is enhanced(162,163). It has no effect on 
cerebral auto regulation and cerebrovascular reactivity to CO2 (164).It causes 
rise or fall in ICP,causing  cerebral perfusion pressure to  decrease(165)The 
induction dose of propofol of 1 - 3 mg/ kg .Apnea occurs in a few minutes. The 
apnea duration and its occurrence is affected by the speed and dose of injection 
and any premedicant given (166). 
 
It is the drug of choice when rapid and complete awakening is desired. It 
is used in TIVA (total intravenous anaesthesia) .It is used as continuous 
infusion for sedation in ICU. Other favorable effects are its antiemetic effects, 
antipruritic, and anticonvulsant actions. It also attenuates bronchoconstriction. 
It decreases ICP in patients with normal or raised ICP. Unfavorable effects are 
pain on injection, apnea, and hypotension. When propofol is given for 48 hours 
or longer at a rate of 4 mg/kg/hr, propofol infusion syndrome may occur. 
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THIOPENTONE 
It is a barbiturate, supplied as a hygroscopic pale yellow powder.It is 
insoluble in water.It is available as a carbonate salt to maintain the alkaline pH. 
Even though it is 80% protein bound it is taken up into brain rapidly within 30 
secs due to itslipophilic nature and   non-ionised fraction of 60% which is high. 
Ampoules containsodium thiopental (500 mg)in nitrogen atmosphere with 6% 
sodium carbonate. When 20ml of water is added, 2.5% solution (25mg/ml) is 
formed. It has a pH of 10.8. The solution is alkaline and kept for 48 hrs safely,it 
is also bacteriostatic. GABA action is enhanced, whereas it blocks the synaptic 
action of glutamate and acetyl choline. The onset of action is 10-30 secs, t1/2 is 
4.6-8.5 minutes, peak effect is 30 secs, and duration of action is 10-30 minutes. 
 
In the barbiturate ring, the sulphur at C2 is replaced by oxygen atom. It 
has a fast onset of action and terminal half-life is reduced from 30 ± 50 h to 10 
± 15 h, due to its chemical structure(Chan et al.,1985) It should  be termed as 
RS-, (+/-).It is a racemate as equal concentrations of (+)-R- and (7)-S-
enantiomers are present. In mice it was found that the hypnotic potential of S-
thiopentoneis more than R-thiopentone (Christensen & Lee 1973; Haley & 
Gidley1976) (Market al., 1977) 
 
In volume depleted patients, or those who have low serum albumin, or 
when non-ionized fraction is increasesas in metabolic acidosis, at a particular 
dose, concentrations in the brain and heart achieved were higher .There is risk 
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of cardiacdepression . When a single dose given as bolus, it is distributed 
quickly to tissues with high perfusion and low volume like brain and spinal 
cord .It then redistributes to lean muscle tissue, then theeffect of the induction 
dose ends. (202) 
 
There was minimal depression of arterial pressure at 10, 15, 20 minutes 
(p<0.05).There were significant increases in cardiac output at 2, 5 minutes. 
(p<0.01), there was decrease in total peripheral resistance at 2 and 5 minutes. 
With thiopental, heart rate changes were also significant at 2minutes (p<0.001), 
5minutes (p<0.01),and at 10 and 15 minutes (p<0.05).There was a decrease in 
stroke volume at 2 minutes  (p<0.01) and 5 minutes (p<0.05).The peripheral 
leg blood flow increased significantly at 2 and 5 minutes.(167) 
 
It causes depression of the myocardium, due to medullary centre 
inhibition, causing   mean arterial pressure (MAP) to decrease.The outflow of 
sympathetics decreases, causing capacitance vessels to dilate. Baroreceptors 
cause reflex sympathetic stimulation, elevation in heart rate occurs due to 
baroreceptor-mediated sympathetic reflex stimulation of the heart when BP or 
cardiac output decreases. These effects are seen clearly in hypovolemic 
patients, those on beta-blockers, and valvular heart disease and cardiac 
tamponade. It causes ventilatory centre in the medulla to get depressed and 
hypoxic and hypercapnic response decreases. It causes spasm of larynx or 
bronchi  as airway reflexes are not suppressed fully. It has 
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antanalgesicproperties. Cerebral metabolic oxygen consumption rate (CMRO2) 
decreases, cerebral blood flow and intracranial pressure also decrease. In EEG 
increased doses, cause burst  suppressionwhich may prevent ischemia of focal 
areas.(168) 
 
It is used as a premedicant and in the induction of anesthesia. Prompt 
onset, and smooth induction are the benefits. In normovolemic patients it 
causes transient decrease in BP that is compensated by tachycardia. It causes 
dose-dependent depression of medullary ventilatory centres. It stimulates an 
increase in enzyme induction which may result in altered drug interactions. 
Intra-arterial injection causes intense vasoconstriction. It is also associated with 
allergic reactions. 
The effects of thiopentone on eight patients who had CAD and normal 
ejection fraction were studied by Reiz et al. Thiopentone decreases myocardial 
oxygen consumption ,caused a decrease in arterial pressure, SVR and 
SVI.(169) 
 
KETAMINE 
Ketamine is a phencyclidine derivative that produces dissociative 
anesthesia. It is soluble in water,has a pKa of7.5.This enables it to be non-
irritant drug in any route of administration.(170–175). 
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It is 10 times more lipophilic than thiopentone and therefore can cross 
the blood brain barrier. Due to rapid redistribution, ketamine has fast onset and 
offset, which is similar in action to thiobarbiturates. It is a noncompetitive 
NMDA antagonist. The onset of sedation was 45 seconds with intravenous 
injection in a dose of 2 mg/kg, and after i.m injection (3 mg/kg) was 4 minutes. 
The time for recovery was 18 mins with IV and 25 mins with IM 
injection.(203) After intravenous injection, half-life of distribution was 
24.1seconds, half-life of redistribution was 4.68 minutes, and half-life due to 
elimination was 2.17hours (176). Peak effect is seen within one minute of 
intravenous injection. Liver is where biotransformation occurs. However, one 
of the most important path way involves cytochromep450enzyme system 
causes N-demethylation of ketamine to nor ketamine.  
 
The induction dose is 1-2 mg/kg intravenously. It produces analgesia, 
induces significant ( 33%) increase in heart rate, mean arterial pressure 
(+28%)(177)and epinephrine levels, there is centrally mediated sympathetic 
nervous stimulation. 
 
There is uptake of catecholamines in the neurons, stimulation of the 
central sympathetic system.These effects are in contrast to the negative 
inotropy on the myocardium. In a healthy individual, increase in arterial blood 
pressure, heart rate, and cardiac output occurs. 
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In the absence of good myocardial function and sympathetic reserve, 
hypotension may occur due to myocardial depression. 
 
Coronary blood flow may not be enough to meet the increased oxygen 
demands due to sympathetic stimulation. 
 
In the presence of increased β-adrenergic stimulation, the failing heart 
cannot  increase the contractility when given ketamine.(178). In such patients, 
there is decrease in cardiac performance and cardiovascular instability occurs. 
In the presence of adrenoceptor blockade, the negative inotropic effects may be 
unmasked.(179) Ketamine is a chiral compound, and until recently was only 
available as the racemic mixture. 
 
The advantages of S (+)-ketamine at lower concentrations, is that it 
causes hypnosis and analgesia, agitated behavior and emergence delirium are 
less. This isomer depresses the myocardium to a lesser extent  than its 
racemate.(180)The R (–) isomer, blocks ischemic preconditioning of the 
myocardium, S (+)-ketamine does not have this action. (181)In contrast, 
however, Hanouz et al (207) demonstrated that both isomerscauses 
preconditioning of the myocardium. The mechanism involvedis that Potassium 
ATP channels are activated, and α- , β- receptorsare stimulated. It has some 
anticonvulsant activity due to its action on NMDA-receptors. Ketamine is both 
anticonvulsant and neuroprotective as  shown by recent studies(182–184) 
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It is unique in the sense that, it induces intense analgesia at sub 
anesthetic doses (0.2-0.5mg/kg), and causes prompt induction of anesthesia at 
higher doses. Analgesia can be produced in labor without neonatal depression. 
Due to its rapid onset of action, it has been used as an intramuscular injection 
drug in mentally challenged patients. In acutely hypovolemic patients, 
induction with ketamine is often done. However, it can be drastic in critically 
ill patients where catecholamine stores are depleted. In asthma patients it is 
useful, as it causes bronchodilation. 
 
It causes emergence delirium. It causes sustained increase in ICP in 
patients with intracranial pathology. It inhibits platelet aggregation. 
 
MIDAZOLAM 
It is an imidobenzodiazepine derivative. It can be used as a premedicant, 
sedative and an induction agent. It has a fused imidazole ring, which is 
responsible for the basic nature, stability of an aqueous solution and for its 
rapid metabolism. The pKa of midazolam is 6.15.The onset of action is about 2 
minutes. The distribution half-life is 6-15 minutes, elimination half-life is 1.7-
3.5 hrs. Peak effect is 30-80 minutes, duration of action is 1-4 hours. 
 
There is no irritation after IV injection. It becomes highly lipophilic at 
physiologic pH. It is one of the most lipid soluble of the benzodiazepines. 
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There is rapid entry of midazolam into the brain tissue.96-97% is bound to 
plasma proteins. GABA chloride channels are opened causing 
hyperpolarization. 
 
Pharmacodynamics 
It causes anxiolysis, hypnosis, muscle relaxation and amnesia. It also 
has anticonvulsant action. It has affinity for glycine receptors in the brain, it 
increases the glycine inhibitory neurotransmitter, and thus it exerts anxiolytic 
effect. It has a high affinity for benzodiazepine receptor about 2 times that of 
diazepam and GABA accumulation occurs. GABA is accumulated because 
GABAreuptake is inhibited. Hypnosis is explained by the excess GABA at 
neuronal synapses. 
 
It was found that the midazolam dose when used together with fentanyl 
was significantly lower than that in the other 2 groups, indicating that fentanyl 
enhanced the degree of sedation, and our results are similar to those of 
others.(185,186) 
 
It is effective in minimizing stress response to intubation 
With a dose of 0.15 mg/kg it caused anesthesia while 0.5 mg/kg caused 
sedation. The induction dose is 0.05-0.15 mg/kg. Sedation dose is 0.5-1 mg 
which is repeated at intervals. An ideal induction agent is one which induces 
sleep in one arm-brain circulation time. Onset and duration of action varies. 
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Hence, it has a delayed onset of action which has the risk of over dosage.Due 
to its nonirritant and short acting nature, sedative doses of 0.05 mg/kg have 
been used during cardiac catheterization (122).For CABG ,midazolam at low 
doses when combined (0.075 -0.15mg/kg)with fentanyl at high doses,75pg/kg 
causes systolic BP to drop by 29 to 33%,diastolic BP to drop by 30 to 31%.The 
stroke index decreases by 25 to 30%.Theleft and right ventricular stroke work 
index decrease by 42 to 46% and 48 to 61 % respectively.This can be explained 
due to increasedpooling of the venous system (124).The elimination is slowed 
with a half-life of 281 mins,after perfusion of the extracorporeal system. As the 
overall peripheral resistance decreases, it causes a significant reduction (2.2%) 
in the mean blood pressure. There is minimal cardiovascular and respiratory 
effects, there is smooth transition to inhalation anesthesiaafter sub anesthetic 
doses. There is almost total absence of excitatory effects.Patient acceptance is 
good, making it a goodalternative to thiopental. The amnesic effectis more than 
double its respiratory depression properties (144). Generally, when compared 
with thiopentone, respiratory depression was less (144,148). 
 
It causes decrease in CMRO2 and cerebral blood flow similar to 
thiopentone and propofol. It is a potent anticonvulsant used for treating status 
epilepticus. It causes dose dependent decrease in ventilation by decreasing 
hypoxic drive. Studies done have shown it may have a role in prevention of 
post op nausea and vomiting.(187).The most important side effect is respiratory 
depression. 
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The agents used during induction commonly in cardiac patients are 
diazepam and flunitrazepam because the effects on the cardiovascular system 
are minimal (Coleman et al in 1973; Cote, Gueret and Bourassa in 1974; 
Stanley et al.in 1976; Clarke and Lyons in1977; Tarnow et al.in1979; 
McCammon, Hilgenberg and Stoelting in1980) 
 
In CAD patients 0.2 mg/kg of midazolam caused the MAP to decrease 
from 92-80 mm of Hg 5 mins after induction. Midazolam in a dose of 0.2 
mg/kg was used and its effect on five CAD-patients who had low cardiac 
output, increased SVR and high filling pressures of the left ventricle was 
studied by Reves, Samuelson and Lewis in 1979.It caused a significant 
decrease of systemic vascular resistance (SVR). Thereby it allowed a 
significant improvement in pump function and a decrease in the increased left 
ventricular filling pressure. However midazolam did not prevent the intubation 
stress response. 
 
Dose in elderly:In elderly, doses of 300 mcg/kg can be given over a time of 
20-30 seconds initially; after 2 to 3 minutes, the effect of sedation is assessed 
and adjustments in dose are made. The dose used in Left ventricular 
dysfunction patients was 0.15-0.2 mg/kg(9) 
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Metabolism: 
Midazolam is metabolized by hydroxylation through hepatic 
microsomal enzymes .The fused imidazole ring is oxidized by the liver rapidly, 
1-hydroxy midazolam is the main metabolite, and 4-hydroxy midazolam are 
formedin small amounts. These are excreted in urine in the form of glucoronide 
conjugates. 
Its rapid onset of action is explained by its high lipophilicity, 
equilibration between plasma and CSF occurs very rapidly. Due to rapid 
clearance and elimination it has a short duration of action. 
The first phase of metabolism is due to the drug distribution. The second 
elimination phase is due to biotransformation. 50% blood flow in liver causes 
midazolam to get cleared fully. Distribution is wide andrapid elimination 
occurs. In elderly, volume of distribution is increased. Volume of distribution is 
larger in women than men. 
 
CLINICAL USES 
It produces sleep and amnesia but no analgesic effect. The induction 
dose is 0.1-0.4 mg/kg. A dose of 0.2 mg/kg can be given safely in high risk 
patients.2 studies were done, White used 0.3mg/kg and induced anesthesia in 
30-60 sec.(188) Finucaine gave the same amount in 4 incremental doses and 
took 4.9 minutes to induce(189).The elderly require a lower dose of 
midazolam.ASA 3 and 4 patients require less dose 0.15-0.2 mg/kg.Age >55 
and ASA >3 patients require 20% less dose than young ,fit patients. 
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In patientsin pediatric age group, who had very low cardiac index, 
Fentanyl has a fast onset and changes in hemodynamics were minimal. 
However, when given along withbenzodiazepines it can cause  circulatory 
depression and requires volume expansion, and in some cases inotropic 
support.(190–193)Heart rate, BP and cardiac index were depressed, by fentanyl 
and midazolam combination in a study done by Revines et al (222). In children 
undergoing CABG, dexmedetomidine and fentanyl was compared with 
midazolam and fentanyl, was compared .The effect on cardiac output in both 
the arms could not be determined, even in the presence of similar SvO2 at the 
recording moments(194).At one hour before surgical stimulus, HR and systolic 
blood pressure were reduced in both groups to a significant extent. However, 
midazolam recorded a significant response to surgical stressand required 
increased supplementation with isoflurane. With the use of 
Dexmedetomidine,analgesic effects was potentiated (195). The changes in 
hemodynamics were similar in both the arms. 
 
Massaut et al. studied the effect in hemodynamics due to midazolam on 
eight anesthetized patients with CAD.  Heart rate decreased by 9%, mean 
arterial pressure by 17%, CI by 9%, and SVR by 12%. They showed the effects 
on endocardial viability to be of benefit, and recommended the use of 
midazolam as an adjuvant  to fentanyl anesthesia especially in patients with 
CAD.(169) 
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In chronic renal failure, anesthesia is induced more rapidly as there is 
more unbound drug to CNS receptors. Males are more sensitive to midazolam 
than females. 
 
Side effects: 
There is no nausea and vomiting. Since it is water soluble, there is low 
incidence of venous irritation and thrombophlebitis. 
 
ETOMIDATE 
It is not chemically related to any other drug. It contains an imidazole 
compound which is carboxylated.  In 1965, it was first reported as one of the 
aryl alkyl imidazole-5-carboxylate esters .It was synthesized by Janssen 
Pharmaceuticals .During animal studies, the hypnotic action was observed. It 
has anti-fungal action. At physiologic pH it was lipid soluble, and at an acidic 
pH, it is soluble in water which is due to the imidazole compound. The original 
formulation included 35% propylene glycol which caused pain during 
injection. This was changed later to a fat emulsion. Myoclonus incidence is the 
same in both. Oral preparation has a higher blood concentration than 
intravenous preparation. Doenicke et al. have shown that the pain during 
injection was due to propylene glycol, a solubilizer.Pain and thrombophlebitis 
can be avoided, by using   a lipid- emulsion formulation. Original preparation 
had high incidence of anaphylaxis which was avoided after they changed the 
preservative. 
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Mechanism of action: 
There are several isomers of which the anesthetic effect is seen in the 
R+ isomer. It acts on the GABA receptor at specific sites and increases the 
affinity of GABA to   these receptors. 
 
Pharmacokinetics: 
Onset of action is 30–60 seconds. Peak effect is seen at 1 minute. 
Duration of action is 3–5 minutes; the induction dose is 0.2-0.6 mg/kg. Volume 
of distribution is large hence there is considerable tissue uptake. After IV 
injection, in a time period of 1 minute, it reaches the peak effect due to rapid 
penetration into the brain. About 76% of the drug is bound to albumin 
independent of the drug concentration. 
 
Metabolism: 
The ethyl ester side chain is hydrolysed to carboxylic acid ester, 
resulting in a pharmacologically inactive compound. Hepatic enzymes and 
plasma esterases mediate this reaction.About 85% is seen as the carboxylic acid 
metabolite in urine and 10-13% as this metabolite in bile. 
 
Cardiopulmonary bypass: 
There is an initial decrease of 34% in plasma etomidate concentration, 
later it decrease to 11% of the prebypass value, there is a further decrease with 
rewarming. 
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Clinical uses: 
In an unstable cardiovascular system etomidate is the drug of choice. 
Induction dose is 0.2-0.4 mg/kg. The onset of unconsciousness starts within 
one arm to brain circulation time. There is alteration in the balance between 
inhibitory and excitatory influences on the thalamocortical tract, hence 
involuntary myoclonic movements occur. By giving opioid before, this can be 
avoided. Awakening is more rapid compared with other barbiturates, there is 
no hangover effect. It does not have analgesic properties. After giving 
etomidate the return of psychomotor function is said to be intermediate to 
methohexital and thiopentone. It may also decrease the duration of seizures, it 
can be used as an alternate drug to propofol and thiopentone. 
 
EFFECTS ON SYSTEMS 
CNS: 
CMRO2 (cerebral oxygen consumption rate) decreases by 35 to 45%, and 
cerebral blood flow is decreased due to vasoconstriction of cerebral vessels. 
Hence it decreases intracranial pressure. The pattern produced in EEG is 
similar to thiopentone, the frequency of excitatory spikes is more with 
etomidate. 
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Cardiovascular system: 
Unlike other induction agents ,it has fast onset and a safe cardiovascular 
profile, and hence  causes  less significant fall  in blood pressure (196–
198).The 30- day mortality and cardiovascular morbidity is increased with the 
use of etomidate, although hypotension during induction is prevented which 
can cause less perfusion of coronaries, arrhythmia, and cardiac arrest. There is 
also prolonged hospital stay.(199) 
 
 It has structural similarities to α2B agonists and results in 
vasoconstriction. This explains its hemodynamic stability. A patient with 
cardiovascular disease depends on the sympathetic tone for maintaining the 
blood pressure, systemic vascular resistance (SVR), and cardiac output. 
Etomidate by its action on α2B receptors negates the need for treatment of post 
induction hypotension and is considered as an ideal induction agent in patients 
with cardiovascular compromise.(200) 
 
The change in heart rate, cardiac output orstroke volume is minimal. 
There is no effect on the sympathetic nervous system or on the function of the 
baroreceptor. During induction it causes more hypertension and tachycardia 
than with the use of propofol. The myocardial oxygen supply to demand ratio is 
well maintained(177).Hence in acutely hypovolemic patients if etomidate is 
given, it can cause sudden hypotension due to parallel changes in SVR and 
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MAP. The only change which was observed was a 10% increase in heart rate, 
(201)hence etomidate is considered to have a stable hemodynamic profile. 
 
RESPIRATORY SYSTEM: 
There is decrease in tidal volume with a compensatory increase in 
respiratory rate. 
It may stimulate ventilation independently, hence it is useful when 
spontaneous ventilation is needed.  
 
Musculoskeletal  
Myoclonus occurs in 50-80% of the patients receiving etomidate. Giving 
fentanyl or benzodiazepine may reduce the occurrence of myoclonus. Giese et 
al. (202) reported that premedication with 100 µg fentanyl significantly 
decreased the rate of etomidate-induced myoclonus; however, it introduced the 
risk of respiratory depression. The mechanism of myoclonus is explained by 
disinhibition of subcortical structures that normally suppress extrapyramidal 
motor activity. 
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patients in etomidate group who developed adrenal suppression received higher 
doses and longer duration of inotropic support postoperatively. The duration of 
adrenal suppression can last between 12–72 hours. The inflammatory response 
is stimulated after cardiac surgery, during bypass surgery, level of  
catecholamine and stress hormones are elevated (205).Cortisol and 
corticosterone which are endogenous cytokines have a role in the maintaining 
the vascular tone and nitric oxide production is inhibited. Since it acts 
synchronously with epinephrine and norepinephrine in maintaining BP,these 
hormones are impaired due to etomidate. During the postoperative period.there 
is an increased vasopressors requirement (205) 
 
 In critically ill who have adrenal suppression CORTICUS trial showed 
that exogenous hydrocortisone did not improve the  survival.(200) 
The cortisol suppressioncaused by a single dose of etomidate is always limited 
to 24 hours,there is no threat of prolonged adrenocortical suppression. In this 
study  the cortisol levels returned to normal levels at twenty-four hours post 
induction.(206). The benefit of minimal cardiac suppression is weighed against 
causing adrenocortical suppression and longer hospital stay. The risk for 30-
day mortality, cardiovascular morbidity, and prolonged hospital stay were 
increased.(207) 
RCT done showed that one group was assigned toreceive etomidate0.3 
mg/kg (n=328) the other group ketamine 2 mg/kg (n=327) for induction. It was  
found that adrenal insufficiency was significantly more in the etomidate group 
than in the ketamine group.(208) 
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The ideal induction agent  
The ideal induction agent obtunds the intubation stress response and also 
maintains hemodynamic stability. The properties of an ideal induction agent 
are as follows: 
Physical properties 
• It should be water soluble & stable in solution and stable on exposure to 
light. 
• It should have a long shelf life with no pain on intravenous injection. 
• It should be painful when injected into an artery and non-irritant when 
injected subcutaneously. There should be a low incidence of 
thrombophlebitis and it should be cheap. 
 
Pharmacokinetic properties 
It should have a rapid onset in one arm-brain circulation time, rapid 
redistribution to vessel rich tissue. It should have rapid clearance and 
metabolism with no active metabolites. 
 
Pharmacodynamic properties 
• It should have a high therapeutic ratio (ratio of toxic dose: minimally 
effective dose) with minimal cardiovascular and respiratory effects. 
• There should be no histamine release/hypersensitivity reactions, no emetic 
effects. 
• There should be no involuntary movements and no emergence nightmares. 
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• There should be no hang over effect, no adrenocortical suppression. 
• It should be safe to use in porphyria. 
 
 Patients with impaired left ventricular function are at a high risk for any 
cardiac surgery. Etomidate is well known to have a stable cardiovascular 
profile. Other conventional techniques like using high dose fentanyl or 
midazolam with fentanyl normal dose have also been used during induction. A 
RCT done in AIIMS compared four induction agents: etomidate, propofol, 
thiopentone and midazolam. The hemodynamic variables were comparable in 
all the four groups. Etomidate was not that effective while midazolam was the 
most effective in preventing stress response to intubationamong the induction 
agents.Among the four groups, there was a comparable decrease in 
hemodynamic parameters.This can be explained by the hypothesis that during 
induction sympathetic stimulation is lost, it cannot be attributed to anesthetic 
induction agents(169)Etomidate was the most cardio stable drug, its effect on 
adrenal suppression was not studied. 
 
Hemodynamic effects of various intravenous induction agents in patients 
with normal LV function 
The magnitude of hypotension is directly proportional to the plasma 
concentration of the induction agent. The concentration depends on many 
factors like age, sex, dose and body weight, cardiac output and infusion rate. 
There is no agreement on the minimum dose of propofol and the method of 
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administeringwhich minimizes hypotension risk. The dose of etomidate utilized 
by various studies ranges from 0.2 to 0.45 mg/kg. The doses at the higher end 
of the spectrum (0.4 mg/kg) for etomidate may cause direct myocardial 
depression(209).The exact induction dose of etomidate for maintaining 
hemodynamic stability has not been zeroed upon as yet. The magnitude of 
variations in SBP, DBP and MAP from baseline was greater when propofol 
was used as an induction agent versus etomidate in comparable doses. The 
mechanisms of arterial hypotension following IV anesthetic induction are 
multifactorial. There is no effect on the sympathetic nervous system, or the 
function of baroreceptors, this explains the safe cardiovascular profile. 
(209,210)It has the ability to bind and stimulate alpha-2B adrenergic peripheral 
receptors causing vasoconstriction.(211). Decrease in systemic blood pressure 
after a bolus injection of propofol is dependent on both vasodilation with 
reduced preload and afterload and myocardial depression (negative inotropic 
action).(209,212–214).It was demonstrated that ketamine, used as the 
anesthetic induction agent during high-dose remi fentanil administration, might 
prevent cardiovascular depression. The choice of ketamine as the induction 
agent during high-dose remifentanil administration might be a safer alternative 
to propofol in patients in whom cardio-vascular depression needs to be 
avoided.(215) 
 
Thiopentone, causes an increase in heart rate(216,217) but in 
infantsthere was no change at lower doses (217,218) and in the elderly there 
62 
 
was a decrease in heart rate (219)Direct effects on the myocardium explains the 
cardiac depression by propofol or thiopentone(220,221).It has indirect action  
on the neuronal system(222).Many studies have reported depression of 
myocardium in a dose-related manner(220,221,223).There are a very few 
studies on the comparison of depressive effect on the myocardium by 
thiopentone versus propofol during induction.(216–218)After induction with 
thiopentone, there was fractional shortening which decreased by 14%, there 
was no change with propofol. Gauss et al (243), Mulier et al (244) found that 
propofol group had significant cardiac depression than equal doses of 
thiopentone given as a single bolus. Left ventricular volume was measured 
using Trans esophageal echocardiographyintraoperatively. 
 
Glissen et al. (224)studied  the effects of propofol, thiopentone and 
etomidate .At clinical concentrations, etomidate did not have any effect on 
contractility of myocardium. Thiopental ,however had a significant negative 
inotropic effect .Haris et al. (225)studied  thiopental in a dose of 4 mg /kg, 
etomidate in a dose of 0.3 mg /kg and propofol in a dose of 2.5 mg /kg along 
with 2 µg/ kg fentanyl in tracheal intubation. In the propofol group, there was a 
decrease in SAP, in the group which received only thiopentone and etomidate 
after intubation, SAP was found to be increased. Vohra et al. compared the 
stress response to intubation with thiopentone in a dose of 5 mg/kg, and 
propofol 3 mg/kg along with fentanyl 1.5mcg/kg. (226).The cardiac outputwere 
measured using thoracic impedance in order to evaluate the hemodynamic 
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responses to intubation. There was  no significant difference in the heart rate  
after induction, but  in both groups there was a statistically significant increase 
in heart rate after intubation (p<0.01). After induction and intubation there was 
a significant decrease in cardiac output. 
 
Pandey et al, did a study (227) comparing the effects of etomidate and 
propofol on hemodynamics and serum cortisol in patients undergoing CABG 
with normal left ventricular function. It was demonstrated that compared with 
propofol,etomidate offers hemodynamic stabilityduring induction of anesthesia. 
 
Studies done on patients with LV dysfunction 
In a study done in AIIMS which compared induction agents in patients 
with coronary artery disease and left ventricular dysfunction, in all four groups, 
the hemodynamic response was similar. Variable changes in systemic vascular 
resistance was noted at induction and intubation, however the stroke volume 
variation and central venous pressure showed no significant changes. 
Inpreventing the stress response to intubation, midazolam was most effective, 
as evidenced by increase in heart rate by 4%, (p=0.12), MAP decreased by 
1%(p=0.77).In the etomidate group, it was the least effective in preventing 
stress response. Heart rate(P = 0.001) and mean arterial pressure (P = 0.001) 
increasedat 1 minute after intubation. All the four induction agents were 
suitable andcan be used for induction in patients with coronary artery disease 
and left ventricular dysfunction, though cardiac index decreased by 30 to 40 % 
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.In such patients with left ventricular dysfunction, experience ofclinician along 
with knowledge of the interactions (concomitant opioid use andpremedication) 
is needed to achieve hemodynamic stability.  
Etomidate which is used during anesthetic induction during cardiac 
surgery which includes CABG ,has the least side effects on respiratory and 
cardiovascular functions, release of histamine was minimal, especially in 
patients withcardiac compromise(228).However, several studies suggest an 
association between etomidate administration, adrenal insufficiency and 
increased mortality in patients undergoing cardiac surgery (229,230).Etomidate 
reversibly inhibits 11-beta-hydroxylase, an important enzyme in steroid 
production in adrenal cortex, which can lead to primary adrenal 
suppression(231).Etomidate blunts the HPA axis responses. HPA axis is 
activated as a body’s mechanism for adapting to illness and stress, which forms 
a component in maintaining the homeostasis of cells and organs.(229) 
Morel et al., (256) did a study comparing propofol or etomidate use 
during induction,the requirement of norepinephrine use during first 48 hours 
after cardiac surgery, the results showthat with a single bolus of etomidate the 
HPA axis response was blunted lasting more than 24 hours, however 
requirement of vasopressors were not increased. They concluded that due to its 
significant inhibition of the HPA axis, etomidate should be used carefully in 
cardiac patients with high risk. 
Another study found no difference in hemodynamic variable such as 
SAP, DAP, MAP and HR after induction of anesthesia and intubation with 
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etomidate versus ketamine-thiopental sodium combination between two 
groups. Due to these results we can consider the combination of ketamine and 
thiopental for anesthetic induction in CABG surgery patients with low EF 
(232) 
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MATERIALS AND METHODS 
 
STUDY SETTING: 
The study was conducted in the cardiothoracic operating theaters and 
cardiothoracic intensive care units in Christian Medical College Hospital, 
Vellore. 
 
Study population: 
49 consenting patients between 14-75 years who underwent cardiac 
surgeries during the 6 month study period in Christian Medical College 
Hospital, Vellore. 
 
Inclusion criteria 
Patients who were scheduled for coronary artery bypass grafting who 
have ejection fraction between 30- 45% were approached and those who were 
willing to participate were included in the study 
 
Exclusion criteria 
• associated valvular heart disease,  
• congestive cardiac failure 
• on mechanical ventilation 
•  severe systemic non-cardiac disease  
• known adrenal insufficiency 
• on chronic steroid use 
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Study period 
It was conducted over a period of 6 months between January to 
September 2016. 
 
Sample size 
A RCT done in AIIMS compared four induction agents etomidate, 
propofol, thiopentone and midazolam. The hemodynamic response was 
comparable in all four groups. Hemodynamic parameters were recorded 
starting from induction at 1 minute intervals till 7 minutes after intubation. 
Baseline Mean arterial pressure and every minute after induction the MAP was 
recorded. The MAP after 3-minute induction in the etomidate group was 75.3 
and MAP in the midazolam group was 68.7. 
 
With expected mean BP 75.3 (SD 10.7) in etomidate group and mean 
BP 68.7 (SD 9.2) in the midazolam group the minimum required sample for the 
study is 36 in each arm. 
 
 
 
 
 
68 
 
Two means- Hypothesis testing for two means 
Standard deviation in group  
I  11.7 11.7 10.7 10.7 7.1 7.1 
Standard deviation in group  
II 16.2 16.2 9.2 9.2 11.1 11.1 
Mean difference 14 14 6.6 6.6 8 8 
Effect size 1.003584229 1.003584 0.663317 0.663317 0.879121 0.879121 
Alpha error (%) 5 5 5 5 5 5 
Power (1- beta) % 80 90 80 90 80 90 
1 or 2 sided 2 2 2 2 2 2 
Required sample size per 
group 16 21 36 48 21 29 
 
The sample size calculation using the Mean BP after 3 minute induction 
and standard deviation in each group was 72 using power of 80 and I have 
chosen the sample size as 72 with 36 in each arm. 
 
Selection of study patient: 
Prior permission was obtained from the institutional review board and 
the ethics committee to conduct the study. Patients who were electively 
planned for cardiac surgery and with a low ejection fraction were given the 
patient information sheet in the OPD. The primary investigator visited them the 
day before surgery and explained about the study .Patients who gave consent 
and fulfilled the inclusion criteria were included in the study and were allocated 
into either of the group, by random allocation. 
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Methodology 
49 patients with moderate to severe left ventricular dysfunction, ejection 
fraction 30-45% were randomly assigned to two groups after informed consent. 
Patients who were scheduled for elective CABG were only included in the 
study.  Exclusion criteria were patients with persistent arrhythmias,associated 
valvular heart disease, congestive cardiac failure, emergency surgery, on 
mechanical ventilation,known adrenal insufficiency, renal disease, history of 
steroid use in the preceding six months, and those with severe systemic non-
cardiac disease, other than diabetes and hypertension. Patients with critical left 
main coronary disease and severe left ventricular dysfunction (Ejection fraction 
(EF) <30%) were also excluded from the study. On the day of surgery patients 
were premedicated with lorazepam 2 mg orally two hours prior to the 
procedure. Base line monitoring was established with pulse-oximetry, invasive 
blood pressure, and five lead ECG. Baseline heart rate (HR), systolic BP, 
Diastolic BP, Mean BP and ST segment at 0 (Before induction) were 
documented. Patients were randomized to the groups with computer based 
random allocation as sealed envelopes. The consultant anesthetist who 
anesthetize the patient used a drug according to the randomization. The 
variables like HR, SBP, MAP, DBP, ST segment, PPV were analyzed and 
documented at 1 minute after induction, 1 minute after intubation, 3 minutes 
after intubation and 5 minutes after intubation. Any rise or fall within 20% of 
base line or a MAP < 60 mmHg is considered significant. As we are 
70 
 
monitoring this continuously we will treat it aggressively if the values go 
beyond 20%.  
 
Hypotension will be treated with Phenylephrine, ephedrine or 
noradrenaline infusion and hypertensive response will be treated with addition 
of fentanyl/ sevoflurane (toincrease the depth of anesthesia). 
 
Baseline data like Heart rate, ST segment analysis in lead II and V5, 
Systolic Diastolic and Mean arterial pressure and pulse pressure variation 
(PPV) were measured. The patients were preoxygenated and received either 
etomidate or midazolam over a period of 60-90 seconds. Fentanyl a dose up to 
3-5 mcg/kg was given during induction in both groups. Titrated doses of 
Etomidate (0.2-0.3 mg/kg) was given over 60-90 seconds in group A patients. 
Titrated doses of Midazolam (0.05-0.1 mg/kg) was given over 60-90 seconds in 
group B patients. Sevoflurane was used to induce and maintain 1MAC end 
tidal anesthetic agent concentration. Rocuronium (1mg/kg) will be used as the 
muscle relaxant to facilitate tracheal intubation. The patients were ventilated by 
bag and mask with oxygen and sevoflurane 2%.  Heart rate, ST, systolic, 
diastolic and mean arterial pressure, and PPV were recorded before induction 
of anesthesia, every minute after induction till intubation, one, three, and five 
minutes after intubation. The first sample for serum cortisol levels was 
measured at 8:00 AM on the day of surgery, the second sample after protamine 
reversal (during C-sample) and the last sample at an interval of 24 hours after 
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the first sample (the next day 8:00 am). Hemodynamic variables were also 
measured at the times stated above. The range for serum cortisol at 8:00 AM is 
5-25 microgram/dl. The study aims to see whether etomidate causes cortisol 
suppression. The data was analyzed to determine which drug is more 
hemodynamically stable during cardiac induction and intubation. Secondary 
outcomes like ICU days, Hospital days and any morbidity and mortality were 
also analyzed. 
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Detailed Diagrammatic Algorithm of the study 
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Patients  who are electively planned forCABG based on 
inclusion and exclusion criteria 
Preoperative informed consent 
Baseline hemodynamic parameters  are recorded 
Patient will receive either etomidate or midazolam during induction  
(by double blinding) 
Hemodynamic variables  will be measured at one  minute intervals 
from induction till five minutes post intubation 
Comparison of hemodynamic response after intubation 
Data analysed to determine which drug is hemodynamically stable 
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Methods 
The agent used in cardiac surgery induction   will be etomidate or other 
conventional techniques like fentanyl and midazolam. Both the groups were 
compared for their hemodynamic variables. The data was analysed to 
determine which drug is more hemodynamically stable. 
 
ii.  Key Criteria 
a. Inclusion Criteria: Patients who were electively planned for coronary 
artery bypass grafting who have ejection fraction between 30- 45% will 
be included in the study. 
b. Exclusion Criteria: Patients with associated valvular heart disease, 
congestive cardiac failure, on mechanical ventilation, severe systemic 
non-cardiac disease and known adrenal insufficiency will be excluded 
from the study. 
iii.  Method of randomization: Random blocks will be generated and the 
patient will be allocated to either arm by randomly allocating based on the 
blocks. 
iv.  Method of allocation concealment: The allocation is concealed using 
sealed envelope technique. 
v.  Blinding and masking: The investigator who collects the data will be 
blinded to the drug. The anesthesia sheets will be marked as either drug A 
or B. 
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ANALYSIS 
 
RESULTS 
 
 
Baseline characteristics expressed as mean +/-SD 
 
 Etomidate n=22 Midazolam n=27 P value 
Age 61.36+/-9 56.37+/-9.3 0.06 
Sex         Male 22 26  
Female 0 1  
Weight 63.86+/-8.49 65.04+/-9.0 0.36 
Height 161.90+/-4.6 163.15+/-7.5 0.5 
EF 42.38+/-2.9 41.6+/-3.6 0.42 
Drug treatment (%)    
Beta blockers 95.5 100 0.45 
CCB 0 3.7 1.0 
ACEI 36.4 22.2 0.35 
ARB 13.6 14.8 1.0 
Diabetes (%) 46.4 53.6 1.0 
Hypertension (%) 47.8 52.2 0.78 
Induction dose 0.2 mg/kg 0.04 mg/kg  
 
 
 
The baseline characters were comparable in both the groups. 
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Serum cortisol level 
 
 
 
 
Serum cortisol values 
 
It can be seen that first sample at induction, in both the groups it is 
within normal values, but the baseline values were higher in the etomidate 
group. (The baseline was comparable. P=0.46) Etomidate causes suppression of 
cortisol values, hence after weaning from CPB, the C sample shows a decline 
in Etomidate group ,not in the midazolam group.(p value=0.001) The third 
sample value is higher in the etomidate than midazolam group. The value is 
reaching near normal in the midazolam group. 
 
 
 
At induction C sample 24 hrs after first sample
Etomidate 17.22 10.16 29.84
Midazolam 15.73 17.21 25.8
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Incidence of significant hypotension 
 
 Etomidate(n=22) Midazolam(n=27) 
Number of cases 7 (31.8%) 14 (51.85%) 
 
 
p=0.88 
 
The number of patients who had MAP less than 60 at any point of time 
during induction among the two groups were compared. 51.85% patients in the 
midazolam developed significant hypotension compared to only 31.8% in the 
etomidate group. (p value between the 2 groups=0.88) 
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DISCUSSION 
 
 
49 patients were assigned to two groupsEtomidate or Midazolam, based 
on random allocation. Baseline demographic characteristics were comparable 
between the two groups. The study was conducted in patients with mild to 
moderate LV dysfunction. However the mean EF was 42.38+/-2.9 vs. 41.6+/-
3.6 in the etomidate and midazolam groups respectively, which qualifies as 
mild LV dysfunction. 
 Etomidate was more hemodynamically stable as seen by the serial MAP values 
which were consistently not less than 20% of baseline in the etomidate group. 
There was significant difference in the MAP value 1 minute after intubation. 
Our results were comparable to studies which have shown etomidate tohave a 
safe cardiovascular profile by Gooding et al., Sun (1991), Yunqi et al., Hosten 
et al., and Pandey et al. The number of patients who had MAP less than 60 at 
any point of time during induction among the two groups was compared. 
51.85% patients in the midazolam developed significant hypotension compared 
to only 31.8% in the etomidate group. (p value=0.88). However we didn’t 
measure the duration of significant hypotension (MAP <60 mmHg) which is a 
drawback of the study. Any blood pressure less than 20% of the baseline was 
treated with pressors and if needed noradrenaline. The patients in the 
midazolam group received more ephedrine, phenylephrine and noradrenaline. 
Even though the difference is not statistically significant,it indirectly indicates 
the increased incidence of hypotension in the midazolam group. 
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In patients who are to undergo CABG, using fentanyl in high doses is an 
established technique in anesthesia.(148,233,234).  The advantage is that there 
is minimal disturbances in hemodynamics, even in patients with poor left 
ventricular function. (149).But fentanyl in high doses is not sufficient to blunt 
the stress response by intubation and additional sedation is required to cause 
amnesia(235,236). However, a combination of midazolam and fentanyl are 
known to result in significant hypotension. In the era of fast tracking, the use of 
high dose fentanyl is almost obsolete as it can result in delayed extubations. We 
decided to use 0.05 -0.1 mg/kg of midazolam, but most consultants who gave 
anesthesia erred on the side of caution and the average dose of midazolam 
administered was 0.04 mg/kg. 43% of patients were more than 60 year old and 
the anesthetist would have accounted for the age for dose reduction.  
 
 Hemodynamic response to intubation were comparable between the 
groups. Both groups suppressed the laryngoscopic response to intubations 
effectively. Our findings are in contrast to Singh etal who found that 
midazolam was more effective than etomidate in prevention of hemodynamic 
response to intubation. We agree with him in his hypothesis that most of the 
hemodynamic changes are attributable to the loss of sympathetic stimulation on 
induction rather than to anesthetic drugs per se. 
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It can be seen that the first sample of serum cortisol at induction, in both 
the groups is within normal values, but the baseline values were higher in the 
etomidate group. (The baseline was comparable. P=0.46) The C sample shows 
a decline in serum cortisol level in Etomidate group but not in the midazolam 
group. (p value=0.001). However the values are within normal limits. The third 
sample value is higher in the etomidate than midazolam group.  
 
In both the groups, third sample 24 hour value were higher as compared 
to baseline values. Hence it can be seen that the adrenal suppression caused by 
Etomidate did not last more than 24 hours. Also the clinical significance of this 
suppression is not clear. Our results are comparable to Zurick et al who showed 
that Etomidate caused  suppression of serum cortisol levelsafter even a single 
dose, leading to cortisol  reduction lasting up to twenty-four hours (206). 
 
The inotrope score ICU stay and hospital stay were less in etomidate 
group compared to midazolam group. The ICU stay in the etomidate group was 
found to be significantly less in the etomidate group. Our results are in contrast 
to CORTICUS trial and other trials done in ICU patients and septic patients 
(230) showing an increased inotropic requirement, morbidity and mortality in 
etomidate group. However our population is different. We agree with A.M 
Zurick etal who concluded that the cortisol suppression caused by a single dose 
of etomidate is mostly limited to 24 hour period (206), there is no threat of 
prolonged adrenocortical suppression. Our data is in agreement with Morel.et 
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al who concluded that a single bolus of etomidate causes the hypothalamic–
pituitary–adrenal axis response to be blunted for more than 24 h in patients 
who are to undergo elective cardiac surgery, but this was not associated with an 
increase in requirement ofvasopressors(229). However our sample size is not 
complete to reach a conclusion. Our results contrasted with Iribarren et al who 
found that the use of etomidate in elective CABG cases was associated with 
relative adrenal insufficiency and increasing requirement of vasopressors 
postoperatively.(230). Our study showed a reduced inotropic requirement and 
ICU stay in etomidate group. Our results contrasted Iribarren who did a study 
in 120 cardiac patients and found that a single dose of etomidate resulted in 12 
-72 hours of adrenal suppression.  
 
In our study there were no reported incidents of pain on injection, 
phlebitis or myoclonus with the use of Etomidate. None of the patients 
developed stroke, renal failure, and myocardial injury .There were 2 cases of 
mortality during the study period. 
 
We couldn’t find any significant ST segment changes during induction 
or intubation. 
 
We could not derive any meaningful association between PPV and 
hypotension. This is partly because we did not fulfill the prerequisite for 
measuring PPV that the patient should be mechanically ventilated. 
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LIMITATIONS OF THE STUDY 
  
We did not complete the required sample size. So the study is 
underpowered to reach any conclusions.  
Duration of hypotension was not documented.  
 
We didn’t analyze the multivariate predictors of hypotension as we 
didn’t complete the sample size. 
 
We didn’t use a pulmonary artery catheter which would have showed us 
the changes in cardiac output, stroke volume and systemic vascular resistance. 
Even though these data would have added to the value of the study we didn’t 
find a favorable risk benefit ratio as most of our patients had only mild LV 
dysfunction. 
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Conclusion 
 
1. Etomidate offered significantly better hemodynamic stability compared 
to midazolam for induction of anesthesia in coronary artery disease 
patients with mild left ventricular dysfunction. 
 
2. Etomidate was comparable to midazolam in suppressing hemodynamic 
response to intubation in the study population. 
 
3.  Even though etomidate suppressed the immediate stress response to 
surgery, the serum cortisol levels were within normal limits and reached 
a comparable value by 24 hours. Also the inotrope score, ICU stay and 
hospital stay were better in etomidate group indicating that the adrenal 
suppression is not clinically significant. 
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